Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Mallinckrodt
Moodys
McKinsey
Boehringer Ingelheim

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR ALENDRONATE SODIUM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Alendronate Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000412 ↗ Osteoporosis Prevention After Heart Transplant Completed Merck Sharp & Dohme Corp. Phase 3 1997-09-01 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗ Osteoporosis Prevention After Heart Transplant Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 1997-09-01 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗ Osteoporosis Prevention After Heart Transplant Completed Columbia University Phase 3 1997-09-01 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00004488 ↗ Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease Completed Children's Hospital Medical Center, Cincinnati Phase 2 1998-10-01 OBJECTIVES: I. Determine the efficacy of alendronate sodium in treating osteopenia (generalized bone density and focal bone lesions) in patients with Gaucher's disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alendronate Sodium

Condition Name

Condition Name for Alendronate Sodium
Intervention Trials
Osteoporosis 15
Postmenopausal Osteoporosis 5
Osteopenia 4
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Alendronate Sodium
Intervention Trials
Osteoporosis 23
Osteoporosis, Postmenopausal 7
Bone Diseases, Metabolic 6
Breast Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Alendronate Sodium

Trials by Country

Trials by Country for Alendronate Sodium
Location Trials
United States 20
Canada 7
Hong Kong 2
Brazil 2
Denmark 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Alendronate Sodium
Location Trials
North Dakota 3
California 3
Colorado 2
Maryland 2
South Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Alendronate Sodium

Clinical Trial Phase

Clinical Trial Phase for Alendronate Sodium
Clinical Trial Phase Trials
Phase 4 6
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Alendronate Sodium
Clinical Trial Phase Trials
Completed 29
Unknown status 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Alendronate Sodium

Sponsor Name

Sponsor Name for Alendronate Sodium
Sponsor Trials
Merck Sharp & Dohme Corp. 12
Mylan Pharmaceuticals 2
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Alendronate Sodium
Sponsor Trials
Other 24
Industry 22
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Mallinckrodt
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.